● Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Condition: Non-small Cell Lung Cancer (NSCLC) · Sponsor: AstraZeneca

PhasePhase 3

Planned participants400

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (205)

Research Site	Chandler, Arizona, United States	Recruiting
Research Site	Gilbert, Arizona, United States	Recruiting
Research Site	Goodyear, Arizona, United States	Recruiting
Research Site	Duarte, California, United States	Recruiting
Research Site	Irvine, California, United States	Recruiting
Research Site	La Jolla, California, United States	Recruiting
Research Site	Loma Linda, California, United States	Recruiting
Research Site	Los Angeles, California, United States	Not Yet Recruiting
Research Site	San Diego, California, United States	Recruiting
Research Site	Grand Junction, Colorado, United States	Recruiting
Research Site	Wheat Ridge, Colorado, United States	Recruiting
Research Site	Newark, Delaware, United States	Recruiting

+ 193 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07291037